Companies › Shenzhen Beike Bio-Technology
1 active drug program in 4 registered trials: 4 Phase 1; Immunology; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| hUC-MSCs treatment (low dose) Allogeneic umbilical cord-derived mesenchymal stem cells | – | Phase 1 | Systemic Lupus Erythematosus (SLE) | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07041801 | hUC-MSCs treatment (low dose) | Phase 1 | Systemic Lupus Erythematosus (SLE) | Immunology | Sep 2027 |
| NCT07041801 | hUC-MSCs treatment (low dose) | Phase 1 | Systemic Lupus Erythematosus (SLE) | Immunology | Sep 2027 |
| NCT07041801 | hUC-MSCs treatment (low dose) | Phase 1 | Systemic Lupus Erythematosus (SLE) | Immunology | Sep 2027 |
| NCT07041801 | hUC-MSCs treatment (low dose) | Phase 1 | Systemic Lupus Erythematosus (SLE) | Immunology | Sep 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.